EGFR and hepatocellular carcinoma: The molecular mechanism attributed to the anti-HCC effects of nitazoxanide drug might be involved in pathways in cancer, PI3K-Akt signaling pathway, MAPK signaling pathway, proteoglycans in cancer, EGFR tyrosine kinase inhibitor resistance, apoptosis, hepatitis B, ErbB signaling pathway, microRNAs in cancer, etc. These findings suggest that all of these mechanisms may be implicated in a synergistic manner in the modulation of HCC by the nitazoxanide drug.